Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Aims To Increase Sales Three Fold In Japan

This article was originally published in PharmAsia News

Executive Summary

Merck KGaA Chairman Karl-Ludwig Kley said Japan is a strategically important market to the company, speaking at a July 24 Tokyo press briefing. With the market launch of cancer drug Erbitux (cetuximab), the company aims to increase Japanese sales three fold to ¥150 billion in 3-4 years. Merck Serono saw its sales grow 13 percent and profit increase by 14 percent in the interim 2008 report. Kley put emphasis on colon cancer drug Erbitux, which obtained approval in Japan on July 16th to treat progressive and relapsed metastatic colon cancer. Kley estimates as a blockbuster drug candidate, sales for Erbitux could exceed €1 billion. At the briefing Merck Serono Japan President, Wayne Paterson also mentioned the Japanese market as a big opportunity and said the company aims to become a stronger cancer drug maker and fertility drug leader. (Click here for more - Japanese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel